The onboarding of Marc Rohman as the CEO of N8 Medical will bolster the development of innovative, anti-infective and anti-inflammatory solutions.
FREMONT, CA: N8 Medical, a renowned biotech company specializing in developing innovative and anti-infective and anti-inflammatory solutions, recently welcomed its new chief executive officer. The pharma industry veteran Marc Rohman joined the N8 executive team as CEO and board member from 1 June 2019.
Based in Dublin, Ohio, N8 is a privately-held company offering antimicrobial surface-protected medical devices. The products delivered by N8 have significantly impacted the clinical sector, leading to the reduction of infections and other related complications. N8 Medical’s CeraShield technology is developed from novel compounds named ceragenins. The non-peptide, small molecule, functional mimetics of naturally-occurring antimicrobial peptides terminate fungi and bacteria by membrane disruption, leading to accelerated cell death.
The N8 team is thrilled to welcome Rohman into the organization, whose knowledge will bolster the initial human trials and the commercialization of the N8 platforms. Rohman has commercialization expertise in the areas of biotechnology, medical device, and pharmaceuticals. He comes with over 30 years of relevant, diverse experience, along with robust commercial and operational leadership.
Rohman was an instrumental asset to Scios during the launch of Natrecor, before Johnson & Johnson acquired the Company for $2.4 billion. Natrecor played a vital role in the treatment of acutely decompensated congestive heart failure. It stands as one of the most successful launches of acute care cardiovascular products. Later, Rohman worked for almost ten years at a private French Pharmaceutical company, Biodex, spearheading their operations in North America. His innovative approaches revolutionized the Company’s commercialization, product development, asset acquisition, and non-profit industry partnerships.
A graduate from Michigan State University, Rohman now lives in Silicon Valley. He offers advice and consultations to startups and early-stage commercial ventures. His decades of experience helped him lead significant product launches in multiple areas, including cardiovascular medicine, acute care, CNS, digestive health, endocrinology, and interventional devices. Rohman voiced his excitement to join the well-positioned, pre-commercial, late-stage company, where his expertise would prove to be an asset.
The appointment coincided with the start of human clinical trials for N8’s flagship product CeraShield endotracheal tube. The preliminary data shows promising results for the product, the first of the proposed anti-infective medical devices designed to target unmet clinical needs and provide meaningful health outcomes.